Datavault AI Inc. Announces a $10M Worldwide Exclusive License Agreement with Scilex Holding Company for Tokenization and Monetization of Real-World Assets (RWA) in Genomic, DNA Data, Diagnostics, Therapeutics, Genetic, and Drug Information

by jezzabellemente, posted in Uncategorized

PHILADELPHIA, Nov 5 (Bernama-GLOBE NEWSWIRE) — via IBN — Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), a leader in AI-driven blockchain solutions focusing on data monetization, asset tokenization, and secure digital marketplaces, today announced that it has granted a worldwide exclusive license, with the right to sublicense, to Scilex Holding Company (Nasdaq: SCLX), for Datavault AI’s proprietary AI-driven technology. This license is tailored for use within the biotech and biopharma industry, enabling Scilex to create and operate a Biotech Exchange platform. By leveraging Datavault AI’s advanced data platforms, Scilex can facilitate secure tokenization, trading, and monetization of biotech assets, including genomic and DNA data, diagnostic and therapeutic products, genetic information, and drug data. This agreement represents a major advancement in commercializing biotech innovations and builds directly on Datavault AI’s established expertise in high-performance computing and data-driven solutions.

Datavault AI believes this technology has the potential to extend into a Pharmaceutical Exchange platform, which could transform the pharmaceutical industry by enabling efficient, secure asset management and monetization.

Datavault AI estimates an opportunity to tokenize approximately $2.0 trillion in pharmaceutical drug sales and diagnostic sales.1 The Company also sees tokenization on such exchange platforms as an alternative for companies to secure non-dilutive funding for developing and commercializing diagnostic and therapeutic products.

This licensing agreement highlights Datavault AI’s robust intellectual property portfolio, including the key pending patent for “Platform and Method for Tokenizing DNA Data” (U.S. Patent Application No. 17/941,623), which establishes a secure framework for tokenizing and exchanging sensitive genetic information. The technology is bolstered by a comprehensive suite of issued and pending patents that power the Biotech Exchange, such as:

  • Issued: “Platform for Management of User Data” (U.S. Patent Nos. 11,593,515; 11,960,622; 12,100,025) and continuations, supporting secure data handling and monetization.
  • Issued: “Portfolio Driven Targeted Advertising Network, System, and Method” (U.S. Patent No. 11,315,150), facilitating data-driven targeting within exchange ecosystems.
  • Pending: “System and Method for Tokenized Minting, Authentication, and Utilization of Assets” (U.S. Patent Application No. 17/842,139), enabling biotech asset tokenization.
  • Pending: “Platform and Method for Tokenization of Corporate Data” (U.S. Patent Application No. 17/941,550), adaptable to biotech datasets.
  • Pending: “System and Method for Tokenized Licensing of Content” (U.S. Patent Application No. 17/842,328), for biotech IP licensing.
  • Pending: “System and Method for Tokenized Affiliate Marketing” (U.S. Patent Application No. 17/842,265), to foster biotech partnerships.
  • Pending: “System and Method for Funding a Virtual Location” (U.S. Patent Application No. 17/842,220), applicable to virtual biotech marketplaces.
  • Pending: “System and Method for Tokenized Event Management” (U.S. Patent Application No. 19/248,284), for biotech events and collaborations.
  • Pending: “System and Method for Registering Claims of Ownership Rights” (U.S. Patent Application No. 18/412,128), ensuring verifiable ownership in data trades.

These innovations collectively form the backbone of a secure, efficient Biotech Exchange, enabling tokenization, valuation, and trading of biotech data assets while upholding compliance and privacy.

Building on Datavault AI’s prior collaborations with Brookhaven National Laboratory, as announced in our June 17, 2025, press release, where we deployed AI-driven supercomputing for biofuel research to enhance fatty acid metabolism efficiency in Brassica napus (canola) using high-performance computational modeling, this license extends our proven AI and data monetization technologies into broader biotech applications. This follows our Sept. 16, 2024, announcement highlighting the Bioenergy Digital Twins Platform at the New York State Digital Summit, emphasizing real-time data synchronization and machine learning integration for bioenergy advancements.

Under the terms of the agreement, Datavault AI will receive a nonrefundable upfront license fee in four equal installments of $2.5 million each, payable by Scilex on or before December 31, 2025, March 31, 2026, June 30, 2026, and Sept. 30, 2026. Additionally, Datavault AI is eligible for sales milestone payments of up to an aggregate of $2.55 billion upon Scilex achieving certain sales milestones.

Terms of License

Under the terms of the agreement, Datavault AI will receive a non-refundable upfront license fee in four equal installments of $2.5 million each, payable by Scilex on or before December 31, 2025, March 31, 2026, June 30, 2026, and September 30, 2026. Additionally, Datavault AI is eligible for sales milestone payments of up to an aggregate of $2.55 billion upon Scilex achieving certain sales milestones.

For more information on Datavault AI, visit www.dvlt.ai.

About Datavault AI Inc.

Datavault AI™ (Nasdaq: DVLT) is leading the way in AI-driven data experiences, valuation, and monetization of assets. The Company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI’s Acoustic Science Division features WiSA®, ADIO®, and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization, and multi-channel interference cancellation. The Data Science Division leverages high-performance computing to provide solutions for experiential data perception, valuation, and secure monetization. Datavault AI’s cloud-based platform serves multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy, and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image, and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI’s technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation, and advertising monitoring. The Company is headquartered in Philadelphia, Pennsylvania.

About Scilex Holding Company

Scilex is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA™” or “SP-102”), which is owned by Semnur (a majority-owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.

Scilex is headquartered in Palo Alto, California. For more information, visit www.scilexholding.com.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, the Company’s license agreement with Scilex, the potential opportunity to tokenize approximately $2.0 trillion in pharmaceutical drug sales and diagnostic sales, Datavault AI’s ability to support Scilex in leveraging its platforms for secure tokenization, trading, and monetization of biotech assets, the potential creation of a Pharmaceutical Exchange platform, expectations as to the opportunity to tokenize pharmaceutical drug sales and diagnostic sales, including the size of such opportunity, future opportunities for Datavault AI, its business strategies, long-term objectives, and commercialization plans, the current and prospective technologies, planned developments and potential approvals, as well as the potential for market acceptance and related market opportunities, and other statements that are not historical facts. These statements are based on management’s current expectations and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Datavault AI. These statements are subject to a number of risks and uncertainties regarding Datavault AI’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, general economic, political, and business conditions; the ability of Datavault AI to achieve the benefits of the license agreement and other transactions contemplated with Scilex, including future financial and operating results; risks related to the outcome of any legal proceedings that may be instituted against the parties regarding the transactions contemplated with Scilex, including the license agreement; the risk that the transactions contemplated with Scilex disrupt current plans and operations; the ability of Datavault AI to develop and successfully market technologies; the ability of Datavault AI to grow and manage growth profitably and retain its key employees; the risk that the potential technologies that Datavault AI develops may not progress or receive required approvals within expected timelines or at all; risks relating to uncertainty regarding regulatory pathways; the risk that Datavault AI has overestimated the size of the target market, willingness to adopt new technologies, or partnerships; risks that prior results may not be replicated; regulatory and intellectual property risks; the risk of failure to realize the anticipated benefits of the transactions contemplated with Scilex; the risk that Datavault AI will not benefit from a Pharmaceutical Exchange platform; and other risks and uncertainties indicated from time to time in Datavault AI’s filings with the SEC. There may be additional risks that Datavault AI presently does not know or that Datavault AI currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Datavault AI’s expectations, plans, or forecasts of future events and views as of the date of this communication. Datavault AI anticipates that subsequent events and developments will cause such assessments to change. However, while Datavault AI may elect to update these forward-looking statements at some point in the future, Datavault AI specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Datavault AI’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements. 

Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
Editor@InvestorBrandNetwork.com

Media Inquiries:
marketing@dvlt.ai
Website: www.dvlt.ai

1References
Sources for Pharmaceutical Drug Sales Data

The data for global pharmaceutical drug sales was primarily drawn from IQVIA Institute reports on global medicine spending, excluding COVID-19 vaccines and therapeutics for consistency. Here is the list of key sources referenced:

Sources for Diagnostic Sales Data

The data for global in vitro diagnostics (IVD) market sales was compiled from market research reports, with forecasts based on observed CAGRs (around 6.9% from 2020-2024). IQVIA provides qualitative insights, but quantitative figures were cross-referenced from other industry analyses for accuracy. Here is the list of key sources referenced:

SOURCE: Datavault AI Inc. 

DISCLAIMER: BERNAMA MREM are not accountable for any causes of website defacement, misuse, or illegal activities connected to cryptocurrency, blockchain, tokenisation, or bitcoin. This material should not be considered as guidance or an opinion, as it does not constitute financial or investment advice. Use this information at your own risk; we are not liable for any losses or damages caused by the republication of this article.

PROFESSOR SPYRIDON FLOGAITIS HONOURED WITH 2025 GLOBAL CITIZEN AWARD

by jezzabellemente, posted in Uncategorized

KUALA LUMPUR, Nov 4 (Bernama) — The prestigious Global Citizen Award has recognised distinguished legal scholar and advocate for public governance, Professor Spyridon Flogaitis for his lifelong commitment to strengthening democratic institutions, upholding the rule of law, and expanding legal access for vulnerable communities.

The annual tribute is presented by leading international residence and citizenship advisory firm Henley & Partners, in partnership with the Swiss non-profit humanitarian organisation Andan Foundation.

“Professor Flogaitis has demonstrated how the law can be a transformative force for peace, dignity, and inclusion. His commitment to justice, democratic resilience, and cross-border collaboration exemplifies what it means to be a global citizen,” said Henley & Partners Chairman and Andan Foundation Founder, Dr Christian H. Kaelin.

Presented at a gala reception during the 19th annual Global Citizenship Conference in London, the award honours individuals who show exceptional courage and commitment towards improving and supporting the global community.

Professor Flogaitis received the Global Citizen Award for his tireless work in advancing public law, legal education, and institutional reform, particularly in regions facing democratic fragility and post-crisis recovery.

As Director and President of the Board of the European Public Law Organization (EPLO), he has led groundbreaking initiatives to improve local governance, train civil servants, and expand access to justice for marginalised groups.

His efforts have had a lasting impact in Southeastern Europe and beyond, fostering legal frameworks that uphold human rights and enable civic participation, Henley & Partners said in a statement.

The Global Citizen Award selection process is based on a majority decision of the Global Citizen Award Committee. The award comprises a bespoke sculptural medal designed by Italian artist Antonio Nocera, an award certificate signed by the Committee Chairman, and a monetary prize of US$20,000 to support the recipient’s humanitarian work. (US$1 = RM4.19)

Henley & Partners also commits to a year-long collaboration with the recipient to raise awareness and amplify their impact through its global network of more than 70 offices.

— BERNAMA

SBC MEDICAL TO UNVEIL Q3 2025 FINANCIAL RESULTS ON NOV 14

by jezzabellemente, posted in Uncategorized

KUALA LUMPUR, Nov 3 (Bernama) — SBC Medical Group Holdings Incorporated (SBC Medical), a global provider of consulting and management services for medical corporations and their clinics, announced it will release its third quarter (Q3) 2025 financial results on Nov 14, before the United States (US) market hours.

SBC Medical in a statement said it will hold an Earnings Call on Nov 17 to discuss the financial results and take questions live.

Participants can register in advance for the conference. Upon registration, attendees will receive access to the dedicated conference viewing page, which includes speaker details and past investor materials.

Presentation materials will be available for viewing and download beginning 10 minutes before the call, and a replay will remain accessible until Nov 17, 2026.

Additionally, the earnings release, accompanying slides, and an archived webcast of this conference call will be available at the company’s Investor Relations website at https://ir.sbc-holdings.com/.

A comprehensive medical group operating a wide range of franchise businesses across diverse medical fields, SBC Medical manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the US and Asia.

— BERNAMA

DAMAC Invites the World to Apply for “The Ultimate DAMAC Islander”

by jezzabellemente, posted in Uncategorized
  • Eight island destinations, all expenses paid by DAMAC for the winner.

DUBAI, United Arab Emirates, Oct 30 (Bernama-GLOBE NEWSWIRE) — DAMAC Properties, the UAE’s largest private luxury real estate developer with an extensive global footprint, has announced a new opportunity for travellers, dreamers, and creators across the globe: the chance to become The Ultimate DAMAC Islander. The selected individual will be a salaried DAMAC employee and embark on a journey as a full-time resident-ambassador, living, exploring, and sharing life across eight exquisite tropical destinations, including Mauritius and Barbados. All expenses, from travel and accommodation to experience, will be fully covered by DAMAC. The unique role from DAMAC offers a unique chance to embody the art of laidback living, experiencing serenity, connection, and escape, all while sharing this journey with a global audience.

A Call to Those Who Dream Bigger
DAMAC’s campaign is part of its wider campaign for DAMAC Islands, inviting people from all walks of life, storytellers, content creators, explorers, and visionaries, to apply and show why they should become The Ultimate DAMAC Islander. The chosen ambassador will serve as an official employee and the face of DAMAC’s flagship tropical island lifestyle, displaying a world defined by sunlit tranquillity, effortless elegance, and discovery.

“This is not just a competition,” said Amira Sajwani, Managing Director, DAMAC Properties. “It is a living, breathing brand story through one person’s journey to become the voice of paradise. We are looking for someone to come on board with a sense of wonder, creativity, and adventure, in short, someone ready to live the life others only dream of.”

The experience will be shared with a global audience through digital platforms, social media stories, and a special content-style series following the Islander’s journey from selection to paradise.

How to Apply
Applications will soon be open globally on DAMAC’s platform www.damacislander.com where candidates can submit their creative entries explaining why they should be chosen as The Ultimate DAMAC Islander.

About DAMAC Properties

DAMAC Properties has been at the forefront of the Middle East’s luxury real estate market since 2002, delivering award-winning residential, commercial and leisure properties across the region and internationally, including in the UAE, Saudi Arabia, Qatar, Jordan, Lebanon, Iraq, the Maldives, Canada, the United States, as well as the United Kingdom.

Since then, the company has delivered more than 49,000 homes with over 54,000 more in diverse planning and development phases. Joining forces with some of the world’s most eminent fashion and lifestyle brands to create tremendous living experiences, such as with Versace, Roberto Cavalli, or de GRISOGONO. With a consistent vision and momentum, DAMAC is building the next generation of luxury living across the globe.

Live the Luxury.

Visit us at www.damacproperties.com

Follow DAMAC Properties on Facebook, X, Instagram, LinkedIn, and YouTube(@DAMACofficial).

For more information, please contact:

Corporate Communications, DAMAC Properties

Tel: +971 4 373 2197

Email: corporatecommunications@damacgroup.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5680a49f-7c11-49f6-8996-76560cfa3617

SOURCE: Damac Properties Dubai Co. PJSC

–BERNAMA

PACIFIC PRIME LEADS EARTHQUAKE RELIEF EFFORT IN NORTHERN CEBU

by jezzabellemente, posted in Uncategorized

KUALA LUMPUR, Oct 31 (Bernama) — Pacific Prime has successfully led an emergency relief mission to support victims of the earthquake that struck northern Cebu last month, leaving hundreds displaced, mourning, and in urgent need of shelter, food, and clean water.

In a statement, Pacific Prime said 57 team members and volunteers helped gather and pack relief goods, with 25 volunteers travelling north to deliver supplies directly to the most severely affected areas.

In addition, staff from Pacific Prime offices in Cebu, Singapore, and Dubai contributed generously, with donations matched by global leaders Neil Raymond and Vittoria Depino. A total of US$5,400 was raised, allowing the team to support over 450 individuals and families across five municipalities. (US$1=RM4.19)

“In times of crises, our team rises – driven by compassion, collaboration, and community spirit. A huge thank you goes out to all the volunteers for their dedication and courage, enduring long hours and tough conditions.

“It is truly inspiring to be part of an organisation that leads with heart, one that lives its values of Impact, Courage, and Selflessness,” said Pacific Prime Cebu head, Lohrie May Labra.

The initial wave of aid reached 354 families and individuals, while the following week, with remaining funds and support from Lacson & Lacson, additional relief such as drinking water, blankets, sleeping mats, and sacks of rice was delivered to over 100 residents still living in tents due to ongoing aftershocks.

This initiative, while not part of the originally planned corporate social responsibility (CSR) activities for the year, became one of the most meaningful, reflecting Pacific Prime’s commitment to its CSR pillars, where Community stands as a core value – driving efforts to support those in need and build resilience in times of crisis.

Established in 2000, Pacific Prime is an award-winning global insurance brokerage and employee benefits specialist that offers individual and corporate insurance solutions.

— BERNAMA